
Sign up to save your podcasts
Or


On this week's BioTech Nation, Moira speaks with Dr. Ijeoma Uchegbu, President of Wolfson College at the University of Cambridge, and Co-Founder & Chief Scientific Officer of Nanomerics, about how chemistry is all around us, all the time. Her book, "Chain Reaction: How Chemistry Shapes Us and Our World" delves into the chemical bonds and reactions that make up life as we know it.
On this episode of Biotech Nation, Dr. Tim Schnabel talks about how Switch Bioworks aims to revolutionize the fertilizer industry by engineering special microbes in place of chemical fertilizers. With a biotech approach, they hope to reduce the cost and environmental impact of industrial fertilizers, and they're already working with the USDA and EPA on trials.
On this episode of BioTech Nation, we look back at the first on-record interview with Theranos founder Elizabeth Holmes, recorded at KQED studios in 2005. At the time of the interview, Holmes was just 21 years old, and her company had already received almost $6 million in funding from investors. Now, over two decades have passed, and Elizabeth Holmes is serving time in prison for fraud. Revisiting the interview today, what can it tell us about where things went wrong?
On this episode of BioTech Nation...
Dr. Harry Selker & Dr. Atul Deshpande of Immediate Therapeutics speak with Moira about a new treatment that could be administered to heart attack patients right away...potentially before they even arrive at the hospital. Already successfully tested in Phase 2, it’s ready to go into final pivotal trials in Ambulances and Emergency Rooms.
This week on BioTech Nation, what is AI-Powered Biology? Dr. Shana Kelley, President of Bioengineering and Head of Biohub, Chicago for the Chan-Zuckerberg Initiative, discusses how AI can be used to accelerate research, interpret data, and transform how new discoveries are made.
This week on Biotech Nation, Heather Turner of LB Pharmaceuticals joins to discuss a drug that’s new to the US, but not-so-new to Europe, where it’s already been in use for a couple of years. Intended for managing neuropsychiatric conditions like Schizophrenia, the drug is taken by several million people, but the approval process in the US has had to start back at square one. We look at why that is, and how LB is working on it.
When you think of FUJIFILM, you might be picturing rolls of camera film...but it turns out that's not all they've been working on. FUJIFILM Biotechnologies Chairman Toshi Iida joins to share more about how they're innovating in the world of biotech.
What if chemotherapy could be delivered in a focused way, directly to a tumor, and only where it's needed? Intensity Therapeutics Founder, President, & CEO Lew Bender shares how they're working to change how chemotherapy is delivered to solid tumors, personalized for each patient, with the hopes of reducing the toll it takes on the body.
This week on BioTech Nation, Jeff Liter of Luminary Therapeutics shares how his team is taking a new approach to advanced cell therapy, in the hopes of making it more accessible and affordable. Rather than formulating a custom treatment using a patient's own cells, they use healthy donor cells that are ready to go. This approach could help more people get treated for cancer and autoimmune diseases like lupus, with just a single dose.
On this episode of Biotech Nation...the story of how the United States' pharmaceutical industry came to be, and the people behind it all. Barry Werth joins Moira to discuss his new book, “The Age of Cures: How American Scientists Saved Your Life", about a handful of individuals who revolutionized research and helped build the drug development ecosystem we have today.
From the publisher's feed

21,786 Listeners

43,796 Listeners

31,957 Listeners

37,785 Listeners

30,565 Listeners

43,335 Listeners

26,156 Listeners

9,182 Listeners

481 Listeners

9,776 Listeners

60 Listeners

112,266 Listeners

16,346 Listeners

5,394 Listeners

16,288 Listeners